Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation

Prostate

Volumn 70, Issue 8, 2010, Pages 866-874

  Kobayashi, Takashi ^a,b   Shimizu, Yosuke ^a   Terada, Naoki ^a   Yamasaki, Toshinari ^a   Nakamura, Eijiro ^a   Toda, Yoshinobu ^a   Nishiyama, Hiroyuki ^a   Kamoto, Toshiyuki ^c   Ogawa, Osamu ^a   Inoue, Takahiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

^c UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Kinase inhibitor; Molecular target therapy; Prostatic adenocarcinoma; Signal transduction

Indexed keywords

ANDROGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; RAPAMYCIN; RHEB PROTEIN; S6 KINASE; MONOMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; NEUROPEPTIDE; PROTEIN SERINE THREONINE KINASE; RHEB PROTEIN, HUMAN; SIGNAL PEPTIDE;

ARTICLE; CANCER CELL; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL CYCLE; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL COUNT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MONOMERIC GTP-BINDING PROTEINS; NEUROPEPTIDES; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 77952308901     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21120     Document Type: Article

References (31)

1. Ferlay J, Bray F, Pisani P, Parkin D. Globocan 2000: Cancer incidence, mortality and prevalence worldwide, Version 1.0. Lyon: IARC Press; 2001.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249.
3. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. NEngl J Med 2003;349(4):366-381.
4. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27(2):222-224. (Pubitemid 32157454)
5. Majumder PK, Yeh JJ, George DJ, Febbo PG, KumJ, Xue Q, Bikoff R, Ma H, Kantoff PW, Golub TR, Loda M, Sellers WR. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 2003; 100(13):7841-7846.
6. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Van Dyke T, Cordon-Cardo C, Pandolfi PP. Pten dose dictates cancer progression in the prostate. PLoS Biol 2003;1(3):E59.
7. Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cell Signal 2004;16(10):1105-1112.
8. Manning BD, Cantley LC. Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003;28(11):573-576.
9. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP. Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008;22(16):2172-2177.
10. Inoue T, Yoshida T, Shimizu Y, Kobayashi T, Yamasaki T, Toda Y, Segawa T, Kamoto T, Nakamura E, Ogawa O. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP cells and its roles in transition to androgen-independent cells. Mol Endocrinol 2006;20(12):3053-3069.
11. Shimizu Y, Segawa T, Inoue T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Terada N, Kobayashi T, Kinoshita H, Kamoto T, Nakamura E, Ogawa O. Increased Akt and phosphorylated Akt expression are associated with malignant biological features of prostate cancer in Japanese men. BJU Int 2007;100(3):685-690.
12. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118(9):3051-3064.
13. Inoue T, Nakanishi H, Inada K, Hioki T, Tatematsu M, Sugimura Y. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells. J Urol 2001;166(6):2134-2141. (Pubitemid 33065238)
14. Latham JP, Searle PF, Mautner V, James ND. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector. Cancer Res 2000;60(2):334-341. (Pubitemid 30070760)
15. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH. RHEB expression in fibroadenomas of the breast. Pathol Int 2008;58(4):226-232.
16. Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N, Kinoshita H, Kamoto T, Ogawa O. Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66(2):332-337.
17. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci USA 1999;96(10):5458-5463. (Pubitemid 29234639)
18. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu promotes androgen independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000;60(24):6841-6845. (Pubitemid 32059149)
19. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, Nesheiwat I, Kong X, Melamed J, Handratta VD, Njar VC, Brodie AM, Yu LR, Veenstra TD, Chen H, Qiu Y. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006;10(4): 309-319.
20. Sobel RE, Sadar MD. Cell lines used in prostate cancer research: A compendium of old and new lines - Part 1. J Urol 2005;173(2): 342-359.
21. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene 2008;27(56):7106-7117.
22. Cinar B, De Benedetti A, Freeman MR. Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin. Cancer Res 2005;65(7):2547-2553. (Pubitemid 40490049)
23. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22(2): 159-168.
24. Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: The expected and, yet again, the unexpected. Cancer Cell 2006;10(2):89-91. (Pubitemid 44175909)
25. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA,WuH, Sabatini DM. mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice. Cancer Cell 2009;15(2):148-159.
26. Memmott RM, Dennis PA. Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009; 21(5):656-664.
27. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118(9):3065-3074.
28. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: Current status. Clin Cancer Res 2006;12(20 Pt 2):6222s-6230s.
29. Saad F. New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treat Rev 2008;34(2):183-192. (Pubitemid 351384327)
30. Ullen A, Lennartsson L, Harmenberg U, Hjelm-Eriksson M, Kalkner KM, Lennernas B, Nilsson S. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44(6):644-650. (Pubitemid 41503612)
31. Dumon JC, Journe F, Kheddoumi N, Lagneaux L, Body JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45(4):521-528; discussion 528-529.